Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: mplaut who wrote (12172)	7/3/2013 12:16:50 PM
From: NTTG	1 Recommendation Recommended By Pogeu Mahone Read Replies (1) \| Respond to of 13111

As an investor, the only way to determine whether 'the new path' you believe the company is on (really not a new path, just punting down the road) has merit is to compare their progress and productivity with known success stories. You seem proud of the 4 employee, lone cowboy PVCT approach, all I can say is don't be surprised about the delays and declining SP, they have been shopping this story around for years now, no takers yet...ever wonder why no one has taken this path before? Sorry, should have pointed to salary and bonuses. But you made my point better that I could have...whether from salaries or current cash burn, the addition of expertise is a low cost / high yield proposition for companies at this stage of development. Chances of success or failure are directly related to the expertise involved, which drug has this management team brought through the development pipe in the past? I think your narrative can be summarized in one word....faith....not a particularly sound investment approach, IMO